FAILURE OF BLOOD-PRESSURE TO INCREASE FOLLOWING ERYTHROPOIETIN THERAPY IN THE RENOPRIVAL STATUS

被引：6

作者：

DESANTO, NG ^{[1
]}

MANZO, M ^{[1
]}

RAIOLA, P ^{[1
]}

LANZETTI, N ^{[1
]}

CAPASSO, G ^{[1
]}

FICOCIELLO, R ^{[1
]}

ANASTASIO, P ^{[1
]}

ESPOSITO, R ^{[1
]}

机构：

[1] UNIV FEDERICO, FAC MED, NAPLES, ITALY

来源：

INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS | 1992年 / 15卷 / 03期

关键词：

ERYTHROPOIETIN; BLOOD PRESSURE; ANEPHRIC STATUS;

D O I：

10.1177/039139889201500304

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Two anephric patients in the course of one year erythropoietin therapy improved their anemic status without changes in Mean Arterial Blood Pressure. The discordant time course behaviour of hematocrit and blood pressure points to the importance of residual renal tissue for blood pressure to develop during erythropoietin therapy in the renoprival status.

引用

页码：144 / 146

页数：3

共 13 条

[1] BENEFITS AND RISKS OF PROTRACTED TREATMENT WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS HAVING HEMODIALYSIS [J].